FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

• Status: Active, not recruiting
• Trial end date: 2022-10-01

Summary

This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows:

• Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies.

• Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors.

• Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.

• Phase: Phase 1

Details

• Lead Sponsor: Fate Therapeutics
• Treatments: Antibodies; Antibodies, Monoclonal; Cetuximab; Immunoglobulins; Mitogens; Trastuzumab